Brain-targeted delivery of Tempol-loaded nanoparticles for neurological disorders.

Brain-targeted delivery of Tempol-loaded nanoparticles for neurological disorders.

Carroll Richard T; Bhatia Deepak; Geldenhuys Werner; Bhatia Ruchi; Miladore Nicholas; Bishayee Anupam; Sutariya Vijaykumar

Journal of drug targeting

2010

2010-11

Brain-targeted Tempol-loaded poly-(lactide-co-glycolide) (PLGA) nanoparticles (NPs) conjugated with a transferrin antibody (OX 26) were developed using the nanoprecipitation method. These NPs may have utility in treating neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease. Central to these diseases is an increased production of reactive oxygen and nitrogen species which may take part in the development of these conditions. As proof of principle, the NPs were loaded with Tempol, a free radical scavenger that has been shown to be protective against oxidative insults. To enhance the delivery of NPs to the central nervous system (CNS), we conjugated the transferrin receptor antibody covalently to PLGA NPs using the

Animals; Rats; Cell Line; Nanoparticles; Polylactic Acid-Polyglycolic Acid Copolymer; Particle Size; Delayed-Action Preparations; Antibodies; Polyethylene Glycols; Blood-Brain Barrier/metabolism; *Lactic Acid; *Polyglycolic Acid; Antioxidants/chemistry/*metabolism; Cross-Linking Reagents/chemistry; Cyclic N-Oxides/chemistry/*metabolism; Free Radical Scavengers/chemistry/*metabolism; Maleimides/chemistry; Spin Labels; Transferrin/*immunology; Tumor; Monoclonal/chemistry/*metabolism

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

665–674

9

18